The Three Marketeers
July 20, 2020
The unprecedented emergency authorization of remdesivir for treating COVID-19 only four months after the virus was discovered was enabled by decades of basic research on the drug’s biological target and drugs with similar parent structures, and was supported by $6.5 billion in NIH funding, according to a study from Bentley University.